Enara Bio's discovery platform wasn't outsourced. It was built internally with integrated computational biology, mass spectrometry, and immunology teams. The CEO believes the most significant innovation and "magic" happens at the interface between these disciplines, a synergy only possible with close internal collaboration.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

The company's foundational insight is that cellular stress is a central mechanism in vastly different diseases. In cancer, they increase stress to kill cells; in degenerative conditions like Parkinson's or hair loss, they aim to decrease stress to restore function. This unifying principle allows their single platform to tackle a diverse therapeutic portfolio.

VC Claire Smith defines "Tech Bio" as a "tech-first" approach, where a novel hardware or software platform is the core innovation, which is then applied to solve biological problems. This contrasts with traditional biotech, which starts with a biological insight (like a target) and then uses a toolbox of existing technologies.

A common strategic error in biotech is assuming a therapeutic delivery system that works for one part of the body (e.g., the liver) constitutes a universal 'platform.' In reality, effective platforms must be built organ-by-organ; a system for targeting tumors is fundamentally different from one for T-cells or kidneys.

The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.

The venture creation strategy for platform biotechs isn't about finding one blockbuster drug. It's a binary bet: either the underlying scientific platform is sound and can repeatedly generate many medicines, or the entire concept fails. There is no middle ground of succeeding with just one product from the platform.

Yosemite's oncology focus stems from Reed Jobs' experience with his father Steve Jobs' pancreatic cancer. However, the firm deliberately adopts a broad, pan-cancer investment strategy, recognizing the interconnectedness of cancer biology across different tissue types.

All therapeutic discoveries fall into two types. The first is a biological insight, where the challenge is to find a way to drug it. The second is a technical advancement, like a new platform technology, where the challenge is to find the right clinical application for it. This clarifies a startup's core problem.